01 // The Crisis
The Problem Nobody Is Solving in Ophthalmology.
In New York, 72% of solo ophthalmologists sit in the succession window today, and only 8 new solo practices have opened across the entire state in the last 5 years. The replacement pipeline has effectively collapsed while the exit wave accelerates.
8%
PE penetration of US ophthalmology · 92% unconsolidated
PESP · Health Affairs
02 // The Market
$4 Billion in Ophthalmology With No Buyer
Average solo ophthalmology practice valuations range from $375,000 to $1.3 million. Thousands of practices are entering the succession window simultaneously. PE walked away from this segment because solo practices produce $150,000 to $500,000 in EBITDA, well below the $1,000,000+ threshold institutional capital needs for multiple arbitrage to work.
$4B
National practice acquisition value through 2035
Total Addressable Market
$1.2B
Tristate serviceable market
Rogue priority targets × avg valuation
1,610
Elite plus High priority tristate targets
Rogue scored records · 70+ score
76%
PE deal volume collapse 2021 to 2024
Federal CM75 deals to 18 · PESPS Data Q1 2026
Historical Analog // Dental 2010
In 2010, institutional capital passed on dental for the same reasons it is passing on ophthalmology in 2026. 6 years later OTPP sold Heartland Dental to KKR at substantially higher valuation.
The "too fragmented, too physician-dependent, too much reimbursement pressure" objections turned out to be irrelevant to the investment thesis after Heartland scaled from 397 offices to 840+ under operator-led management. American ophthalmology now sits at the same inflection, with 4,300 solo practices retiring by 2030, 70.4% of the market still in physician hands, and no consolidator built for the segment.
Operating Company
Healthcare has no shortage of capital. What solo ophthalmology has lacked is an operator class structured around CPOM, AKS, and fair market value constraints at the scale where these practices live. The $4 billion sits in transition because the matching buyer class never existed.
03 // The Pattern
The Recurring Pattern Across Solo Ophthalmology Succession.
The acquirable opportunity in solo ophthalmology lies in healthy practices running below capacity, where the founder pulled back years before retirement and never replaced the management bandwidth. The clinical foundation stays intact while the operational layer deteriorates. The gap between sustained patient demand and contracted physician availability is the recurring source of unlocked enterprise value across the pipeline.
☍
Title
The founder reduces the clinical schedule, marketing stops, and operations drift while the clinical reputation stays intact. Patients continue to ask for appointments the practice can no longer fully serve.
△
Capacity Gap
Patient demand persists at full pre-pullback levels while physician availability contracts, wait times stretch, and some patients leave for shorter-wait alternatives. The clinical reputation prevents the practice from collapsing entirely, but capacity sits below what the market still wants.
□
Operational Fix
Take the business off the founder's plate by installing a successor physician and bringing in professional MSO management. Revenue recovers because patient demand never left in the first place.
◯
Recurring Pattern
The same dynamic repeats across the targets identified in the Verdira pipeline. The platform model is built around the recurring pattern itself, so the playbook scales beyond any single practice.
04 // The Model
How Verdira Operates
We acquire solo ophthalmology practices from retiring physicians and install a successor physician who owns the clinical entity. The physician keeps full clinical autonomy. Verdira owns and operates the MSO, which handles every non-clinical function including billing, staffing, rent, equipment, technology, marketing, and compliance. Under the MSA framework, the MSO collects a fixed monthly Management Fee paid by the PC, set at fair market value and locked in dollar terms so the fee never varies with revenue, volume, or referrals, which is what makes the structure CPOM-compliant and AKS-safe by design.
FMV
NationaFixed Management Fee independent of revenue or volumel practice acquisition value through 2035
CPOM Compliant
Annual
Structured contractual escalator
MSA Locked at Signing
Permanent
MSO operating ownership in perpetuity
No Fund Timeline
Near 0
Marginal cost per practice added
Same Platform Infrastructure
05 // Structure
Why Ophthalmology Sits Outside Public Market Cycles
The Verdira operating model is structurally insulated from the credit and equity market cycles that drive PE-backed healthcare platforms. Four mechanics compound independently of macro sentiment.
06 // Philosophy
We Optimize. We Do Not Cut.
Private equity acquires ophthalmology practices and immediately cuts staff, adds volume quotas, strips clinical autonomy, and grinds margins to hit a 3 to 5 year exit multiple. The model carries a documented consequence on the physicians inside it.
Higher physician turnover at PE-acquired practices compared with physician-led independent groups.
Health Affairs 2025
78%
AJO 2024
Ophthalmology trainees who refuse PE employment
100%
Verdira Operating Standard
Staff retention is the operating standard at every acquisition
Anti-PE
Contractual Protection
Explicit MSA assignment clause prevents PE rollup